Histopathological Techniques and PCR on Tissues Included in Paraffin for the Diagnosis of Tuberculosis
NCT ID: NCT02978131
Last Updated: 2019-03-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
20 participants
OBSERVATIONAL
2015-05-31
2017-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
There are also latent forms (1/3 of the world population) of the infection that can be reactivated in one case out of ten. Each year, about 2 million people die of tuberculosis and 9 million new cases are identified, including about 500,000 cases of MDR TB.
The spread of this disease as well as the increasing number of cases of MDR tuberculosis, reinforce the need for research and development of strategies of diagnosis and management of this affection.
Nowadays, the culture is the gold standard for the TB diagnosis but this technique needs at least three weeks to be performed. The objective of this study is to evaluate the sensitivity and specificity of histopathological and molecular techniques (PCR) on paraformaldehyde fixed and embedded in paraffin tissues for a faster diagnosis of tuberculosis in current practice, in order to administrate an efficient treatment as soon as possible.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Impact of New Immunological Diagnosis Tests of Latent Tuberculosis Before Anti TNF Therapy
NCT00811343
Diagnosis Test of Real-time Polymerase Chain Reaction (RT-PCR) for Pulmonary Tuberculosis
NCT06284187
Probe Melting Technology for Rapid Detection of Drug Resistant Tuberculosis
NCT02776150
New Strategies for Assessment of the Persistence of Viable Bacilli in Latent and Active Tuberculosis
NCT05621343
Determining Risk in Latent Tuberculosis
NCT01571739
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with a clinical diagnosis of TB
Patients with a clinical diagnosis of TB. Retrospective study on biopsy samples
Histopathological study
Molecular study (Polymerase chain reaction)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Histopathological study
Molecular study (Polymerase chain reaction)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients who performed biopsy before inclusion
Exclusion Criteria
* Patients who refuse to participate
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Lille Catholic University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Colette Creusy, MD
Role: PRINCIPAL_INVESTIGATOR
GHICL
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OBS-032
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.